STEPHEN MORLEY: Open Payments
NPI 1316291396 · NORTH HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 39 payments from 13 companies in 2025. Trend: 2023 $989 · 2024 $887 · 2025 $936
Food & beverage: $852Education: $84
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $136 |
| Supernus Pharmaceuticals, Inc. | 5 | $108 |
| Neurocrine BioSciences, Inc. | 5 | $102 |
| Teva Pharmaceuticals USA, Inc. | 2 | $98 |
| E.R. Squibb & Sons, L.L.C. | 4 | $98 |
| ABBVIE INC. | 3 | $75 |
| Corium, LLC | 3 | $68 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Axsome Therapeutics, Inc. | 2 | $49 |
Products named: CAPLYTA, Qelbree, INGREZZA, COBENFY, VRAYLAR, Azstarys, Jornay PM, FANAPT.
Industry payments across CT — which companies pay providers there.
